{"filings":[{"id":95355,"accession_number":"0001193125-26-215676","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MBX 4291 Phase 1 shows 7% mean weight loss at 8 weeks; MBX 5765 nominated","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded data: mean weight loss 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, incl. 2 placebo).","PK profile supports once-monthly dosing: T1/2Cmax ~26 days, Tmax 13–14 days, dose-proportional PK from 15-180 mg.","MBX 5765 nominated as amycretin prodrug (GLP-1/GIP/GCG/DACRA agonist); IND-enabling studies expected Q2 2026.","Imapextide achieved POC in PBH Phase 2a (glucose nadir +34% at 200 mg); company will not pursue Phase 2b.","12-week MAD Part C data for MBX 4291 remain on track for Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95354,"accession_number":"0001193125-26-210825","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MBX Biosciences Q1 net loss $23.5M; Phase 3 canvuparatide start on track for Q3 2026","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities of $440M; expected to fund operations into 2029.","R&D expenses $18.5M (down from $22.4M YoY); G&A expenses $8.8M (up from $4.1M YoY).","Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism to initiate in Q3 2026 after successful FDA End-of-Phase 2 meeting.","Appointed Mark Soued as Chief Commercial Officer; he led Alnylam's US amyloidosis business and AMVUTTRA launch.","Obesity Day on May 11 to present initial blinded MBX 4291 Phase 1 data; amycretin prodrug nomination expected this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108367,"accession_number":"0001193125-26-103118","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MBX Biosciences reports FY2025 net loss of $87M; Phase 3 canvuparatide on track for Q3 2026","event_type":"earnings","confidence":"high","bullets":["Net loss FY2025 $87.0M vs $61.9M in 2024; R&D expenses $79.2M, up from $57.4M.","Pro forma cash & investments $459.1M including $85.4M ATM net proceeds; runway into 2029.","Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism to initiate Q3 2026 after successful End-of-Phase 2 FDA meeting.","MBX 4291 (obesity) 12-week MAD data expected Q4 2026; two additional obesity candidates to be nominated in Q2 and Q3 2026.","Appointed Laurie Stelzer to Board and Karen Basbaum as CBO in early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108366,"accession_number":"0001193125-26-097611","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MBX Biosciences successful End-of-Phase 2 FDA meeting; Phase 3 trial for canvuparatide in Q3 2026","event_type":"regulatory","confidence":"high","bullets":["Phase 3 double-blind placebo-controlled trial will enroll ~160 patients; 3:1 randomization, 4-week fixed 600 ug dose then 18-week titration, 4-week maintenance.","Primary endpoint: proportion of participants achieving normal serum calcium and independence from conventional therapy at Week 26; open-label extension after.","Canvuparatide granted Orphan Drug Designation by European Medicines Agency for chronic hypoparathyroidism.","Company on track to initiate Phase 3 trial in Q3 2026 based on FDA feedback from End-of-Phase 2 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108365,"accession_number":"0001193125-26-079286","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","9.01","5.02"],"status":"ready","headline":"MBX Biosciences CFO Richard Bartram resigns; John Smither named interim CFO","event_type":"leadership","confidence":"high","bullets":["CFO Richard Bartram resigns effective March 15, 2026; will serve as consultant post-resignation.","John Smither appointed Interim CFO effective March 16, 2026; base salary $325k, target bonus 40%, $25k sign-on.","Lease entered for 13,642 sqft office/lab in Burlington, MA; aggregate base rent ~$3.4M over 4-year term.","Departure not due to dispute; search for permanent CFO underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108364,"accession_number":"0001193125-26-039475","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MBX Biosciences raises ~$87.1M in ATM offering; 2.25M shares sold at $38.76 VWAP","event_type":"other_material","confidence":"high","bullets":["Closed sale of 2,250,986 shares at a volume-weighted average price of $38.76 for gross proceeds of approximately $87.1 million on February 4, 2026.","Shares sold under Open Market Sale Agreement with Jefferies dated November 6, 2025, and shelf registration statement effective December 8, 2025.","Net proceeds to fund clinical-stage programs, discovery R&D, working capital, and potential in-licensing or acquisitions.","Following this sale, up to $62.9 million in additional common stock remains available for future ATM sales through Jefferies.","Company retains flexibility to use proceeds for general corporate purposes and complementary business investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108363,"accession_number":"0001193125-26-018700","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MBX Biosciences appoints Laurie Stelzer as independent director and audit committee chair","event_type":"leadership","confidence":"high","bullets":["Laurie Stelzer appointed as Class I director effective Jan. 20, 2026, filling an existing board vacancy.","Stelzer will serve as chair of the Audit Committee, replacing Ed Mathers on that committee.","She brings CFO experience from Kailera, Orna, Mirati, Arena, Halozyme, and board roles at Sionna, PMV, Spyre.","Board size increased to eight directors; Stelzer is independent under Nasdaq standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108362,"accession_number":"0001193125-26-009642","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"MBX Biosciences reports $373.7M cash, expands obesity pipeline with two new candidates in 2026","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of $373.7M at Dec 31, 2025; runway into 2029.","Canvuparatide (HP): 1-year follow-up data from Phase 2 in Q2 2026; Phase 3 start on track for Q3 2026.","MBX 4291 (obesity, GLP-1/GIP prodrug): 12-week Phase 1 data expected Q4 2026; potential once-monthly dosing.","Two additional obesity candidates to be nominated in Q2 and Q3 2026: amycretin prodrug and GLP-1/GIP/GCGR triple agonist.","Imapextide (PBH): Phase 2a data in Q2 2026; once-weekly dosing preferred in patient surveys."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124816,"accession_number":"0001193125-25-268146","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"MBX posts positive Phase 2 results for canvuparatide; Q3 net loss $21.6M; cash $391.7M","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $21.6M vs $18.1M YoY; cash and equivalents $391.7M (includes $200M offering proceeds) funding into 2029.","Positive Phase 2 topline: 63% of canvuparatide-treated patients met composite endpoint at 12 weeks; 79% at 6 months in open-label extension.","Dosed first participant in Phase 1 trial of MBX 4291 (GLP-1/GIP co-agonist) for obesity; results from MAD portion expected Q4 2026.","Dosed first patient in Phase 2a trial of imapextide for post-bariatric hypoglycemia; results expected Q2 2026.","Director changes: James Cornelius resigned Oct 31; Steven Hoerter appointed executive chairman effective Nov 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141513,"accession_number":"0001193125-25-220432","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MBX Biosciences raises $187.5M via public offering of 11.1M shares at $18.00","event_type":"other_material","confidence":"high","bullets":["Offering of 11,108,055 shares at $18.00 per share; underwriters have 30-day option for up to 1,666,208 additional shares.","Net proceeds of $187.5M; funds to advance three clinical-stage programs plus discovery R&D and corporate purposes.","Underwriting agreement with J.P. Morgan and Jefferies as representatives; offering closed September 26, 2025.","Registration statements on Form S-1 and S-1MEF became effective September 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141512,"accession_number":"0001193125-25-210049","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MBX Biosciences' canvuparatide meets Phase 2 primary endpoint: 63% responder rate, p=0.042, 79% at 6 months OLE","event_type":"other_material","confidence":"high","bullets":["Primary composite endpoint met: 63% (30/48) of canvuparatide patients vs 31% (5/16) placebo at Week 12 (p=0.042).","Open-label extension: 79% (44/56) achieved responder status at 6 months, including placebo crossovers.","Safety: well-tolerated, no treatment-related SAEs or discontinuations; injection site reactions 19% vs 13% placebo.","Company plans to initiate Phase 3 trial of once-weekly canvuparatide in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141511,"accession_number":"0001776111-25-000007","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MBX Biosciences doses first participant in Phase 1 trial of obesity drug MBX 4291","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial is randomized, double-blind, placebo-controlled; Part A: 5 SAD cohorts (8 each, 3:1 randomization).","Part B: 3 MAD cohorts (4 weekly doses, 8 each, 3:1 randomization); plus optional 12-week MAD cohorts (30 each, 2:1).","Topline results anticipated in 2027; preclinical data support once-monthly dosing and improved GI tolerability.","MBX 4291 is a long-acting GLP-1/GIP co-agonist prodrug for obesity, designed for best-in-class weight loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141510,"accession_number":"0000950170-25-104602","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MBX Biosciences Q2 net loss $19.4M; cash $224.9M; canvuparatide Phase 2 data on track for Q3 2025","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M for Q2 2025 vs $15.9M in Q2 2024; R&D expenses increased to $17.7M.","Cash, equivalents and marketable securities $224.9M as of June 30, 2025; expected to fund operations into mid-2027.","Phase 2 Avail trial of canvuparatide in hypoparathyroidism topline results expected in Q3 2025.","Phase 2a trial of imapextide (post-bariatric hypoglycemia) and Phase 1 trial of MBX 4291 (obesity) to initiate in Q3 2025.","Appointed Dr. Andreas Moraitis as SVP of Clinical Development in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159358,"accession_number":"0000950170-25-086546","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MBX Biosciences submits IND for MBX 4291, once-monthly GLP-1/GIP obesity prodrug","event_type":"other_material","confidence":"high","bullets":["IND submitted to FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug for obesity.","Designed for once-monthly administration to potentially improve adherence and GI tolerability.","Phase 1 trial expected to start Q3 2025 in healthy overweight volunteers.","Candidate developed using MBX's proprietary PEP platform technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159357,"accession_number":"0000950170-25-083447","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MBX Biosciences posts updated corporate presentation; no material financial or pipeline updates disclosed","event_type":"other_material","confidence":"low","bullets":["Company posted updated corporate presentation on its website on June 9, 2025.","Presentation is dated June 2025 and features the 'Precision Endocrine Peptides' tagline.","No specific data on clinical programs, financials, or guidance changes were provided in the filing.","Exhibit 99.1 (presentation) was only partially reproduced; full content not available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159356,"accession_number":"0000950170-25-082697","cik":1776111,"company_name":"MBX Biosciences, Inc.","ticker":"MBX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"MBX Biosciences elects Tiba Aynechi and Kent Hawryluk as Class I directors; Carl Gordon departs board","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Tiba Aynechi (24.3M for) and P. Kent Hawryluk (24.4M for) to three-year terms ending 2028.","Carl L. Gordon, Ph.D., CFA departed the board effective June 5, 2025; his term ended at the annual meeting.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 27.8M for, 3,467 against.","Annual meeting held June 5, 2025; 33.4M shares outstanding as of April 11 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}